Semaglutide Injection Guide: Sites, Technique & Dosing (2026)

Overview

Semaglutide — marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management — is administered as a once-weekly subcutaneous injection. Proper injection technique is essential for consistent drug absorption, minimizing discomfort, and reducing the risk of injection site reactions. Whether you are using a prefilled pen device or reconstituting from a vial (common with compounded formulations), understanding the correct procedure helps ensure you receive the intended dose safely. This guide covers the step-by-step injection process, recommended anatomical sites, the standard dose escalation schedule, storage requirements, and the most common mistakes patients make. This content is educational only and does not constitute medical advice. Always follow the specific instructions provided by your prescribing healthcare provider, as individual dosing protocols may vary based on your medical history and treatment goals.

Choosing the Right Injection Site

Semaglutide is administered as a subcutaneous injection, meaning the needle delivers medication into the fatty tissue layer just beneath the skin — not into muscle. The three FDA-recommended injection sites are the abdomen (at least two inches from the navel), the front of the thigh (middle third), and the back of the upper arm. Each site offers adequate subcutaneous tissue for proper absorption, though individual body composition may make certain sites more comfortable than others. The abdomen is the most commonly used site because it typically has the most accessible subcutaneous fat and allows patients to self-inject easily while seeing the injection area. The thigh is a convenient alternative, particularly for patients who find abdominal injections uncomfortable. The upper arm is viable but often requires assistance from another person, as it is difficult to pinch the skin and operate the pen simultaneously with one hand. Clinical pharmacokinetic studies have shown that semaglutide absorption is comparable across all three sites, so choosing between them is primarily a matter of comfort and convenience. However, rotation between sites is important to prevent lipodystrophy — localized changes in subcutaneous fat that can develop when the same small area is injected repeatedly over months. A simple rotation strategy is to use a different quadrant of your chosen area each week or alternate between two different anatomical sites.

• Abdomen: most popular site, at least 2 inches from navel, avoid areas with scars or bruises
• Front of thigh: middle third of the upper leg, easy to access for self-injection
• Back of upper arm: may require assistance from a partner or caregiver
• Rotate injection sites weekly to prevent lipodystrophy and reduce local irritation
• Do not inject into areas that are red, bruised, tender, or hardened

Prefilled Pen vs. Vial and Syringe: Key Differences

Semaglutide is available in two primary formats: the manufacturer's prefilled pen device (Ozempic or Wegovy pens) and multi-dose vials typically associated with compounded semaglutide formulations. The prefilled pen is the standard delivery method for brand-name products and is designed for ease of use. Each pen contains multiple doses, and the patient dials the prescribed dose using a selector on the pen. The pen uses a fine-gauge needle (typically 30-32 gauge) that attaches to the pen tip before each injection. Pen injections require minimal training — the patient simply dials the dose, inserts the needle subcutaneously, presses the injection button, and holds for a specified count (usually 6-10 seconds) to ensure complete delivery. Compounded semaglutide, which has become widely available through 503B pharmacies and telehealth platforms, is typically supplied in multi-dose vials requiring the patient to draw the correct volume using an insulin syringe. This method demands more precision: the patient must understand concentration (mg/mL), calculate the correct volume for their prescribed dose, draw accurately using the syringe markings, and ensure no air bubbles remain. While drawing from a vial provides more dosing flexibility, it introduces more opportunities for error. Patients using vial-and-syringe methods should have their healthcare provider demonstrate the technique and should practice with supervision before self-administering. Regardless of format, the injection itself — the subcutaneous technique, site selection, and rotation — is identical between pen and vial delivery.

• Prefilled pens: dial-a-dose simplicity, less room for error, slightly higher cost
• Vials and syringes: require volume calculation, more dosing flexibility, lower cost for compounded formulations
• Use insulin syringes (29-31 gauge, 0.5 or 1 mL) for vial-based injections
• Always verify concentration (mg/mL) before calculating your injection volume
• Ask your provider to demonstrate vial technique before self-administering

Step-by-Step Injection Technique

Proper technique minimizes discomfort, reduces the risk of complications, and ensures you receive the full prescribed dose. Begin by washing your hands thoroughly with soap and water. If using a pen, attach a new needle by removing the outer cap, pressing the needle straight onto the pen tip, and twisting until secure. Remove both the outer and inner needle caps. For pen users, perform a safety test by dialing 0.25 mg (or the pen's test dose marking), pointing the needle upward, and pressing the injection button until a drop appears at the needle tip — this confirms the pen is functioning and removes air. For vial users, clean the rubber stopper with an alcohol swab, draw the correct volume of air equal to your dose into the syringe, inject the air into the vial, invert the vial, and slowly withdraw the prescribed volume. Tap the syringe gently and push out any air bubbles. Next, clean the injection site with an alcohol swab and allow it to air-dry completely — injecting through wet alcohol can cause stinging. Pinch a fold of skin at the chosen site using your thumb and index finger to lift the subcutaneous tissue away from the underlying muscle. Insert the needle at a 90-degree angle (or 45 degrees if you have very little subcutaneous fat) in a smooth, steady motion. For pen injections, press the dose button firmly and hold for at least 6 seconds after the dose counter returns to zero. For syringe injections, depress the plunger slowly and steadily. After injection, release the skin pinch and withdraw the needle straight out. Do not rub the injection site. Dispose of the needle in an FDA-cleared sharps container immediately.

• Wash hands thoroughly before handling any injection supplies
• Perform a pen safety test before each injection to verify function and clear air
• Clean the injection site with alcohol and let it air-dry completely
• Pinch skin and insert needle at 90 degrees (45 degrees for very lean individuals)
• Hold the pen button for at least 6 seconds after the counter reaches zero
• Do not rub the site after injection — gentle pressure with a cotton ball is acceptable
• Dispose of needles in a proper sharps container, never in household trash

Dosing Schedule and Escalation Protocol

Semaglutide uses a gradual dose escalation schedule designed to minimize gastrointestinal side effects — particularly nausea — that are most common during the initiation phase. For weight management (Wegovy), the FDA-approved escalation is: 0.25 mg weekly for weeks 1-4, 0.5 mg weekly for weeks 5-8, 1.0 mg weekly for weeks 9-12, 1.7 mg weekly for weeks 13-16, and the maintenance dose of 2.4 mg weekly from week 17 onward. For type 2 diabetes (Ozempic), the schedule is 0.25 mg weekly for 4 weeks, then 0.5 mg weekly, with an option to increase to 1.0 mg or 2.0 mg based on glycemic response. The escalation timeline is a minimum recommendation — if you experience significant nausea or gastrointestinal discomfort at any step, your healthcare provider may extend the duration at that dose level before advancing. Some providers keep patients at 1.0 mg or 1.7 mg if they achieve adequate results without escalating to the maximum dose. Compounded semaglutide may follow different escalation protocols depending on the prescribing provider's approach, and concentrations can vary between compounding pharmacies. Never adjust your dose without consulting your healthcare provider. Missing a dose should be handled according to your provider's guidance: generally, if fewer than 5 days have passed since the missed dose, take it as soon as possible; if 5 or more days have passed, skip the missed dose and resume on your regular schedule. Consistency in timing — injecting on the same day each week — supports stable blood levels and may reduce side effects.

• Week 1-4: 0.25 mg weekly (initiation dose)
• Week 5-8: 0.5 mg weekly
• Week 9-12: 1.0 mg weekly
• Week 13-16: 1.7 mg weekly
• Week 17+: 2.4 mg weekly (maintenance dose for weight management)
• Escalation can be slowed if GI side effects are significant — talk to your provider
• Inject on the same day each week for consistent blood levels

Storage and Handling Requirements

Proper storage is critical for maintaining semaglutide's potency and safety. Unused prefilled pens and unopened vials must be stored in a refrigerator at 36-46°F (2-8°C). Do not freeze semaglutide — freezing damages the protein structure and renders the medication ineffective, and frozen pens or vials should be discarded even if subsequently thawed. Once an Ozempic or Wegovy pen is in use (first injection taken), it can be stored at room temperature (up to 86°F / 30°C) or in the refrigerator for up to 56 days (8 weeks), after which any remaining medication must be discarded regardless of the remaining volume. For compounded semaglutide in vials, storage duration after first puncture varies by pharmacy — many specify 28 days refrigerated — so check the label or consult your pharmacist. Protect semaglutide from direct light and heat. Do not store pens with a needle attached, as temperature changes can cause medication to leak out or air to be drawn in, affecting dose accuracy. When traveling, use an insulated cooler bag with ice packs (avoiding direct contact between the pen and ice to prevent freezing) for transport, and never leave semaglutide in a hot car, direct sunlight, or checked luggage where it may be exposed to extreme temperatures. If you are uncertain whether your medication has been compromised by temperature exposure, do not use it — contact your pharmacy for guidance. Inspect the solution before each injection: it should be clear and colorless to slightly yellow. Do not use semaglutide that appears cloudy, discolored, or contains particles.

• Unused pens/vials: refrigerate at 36-46°F (2-8°C), do not freeze
• In-use pens: room temperature or refrigerator for up to 56 days
• Compounded vials: typically 28 days after first puncture — check label
• Never store pens with a needle attached
• Protect from light, heat, and extreme temperatures during travel
• Discard if frozen, cloudy, discolored, or past expiration date

Common Mistakes and How to Avoid Them

Even experienced patients can develop habits that compromise injection safety or efficacy. One of the most common mistakes is failing to rotate injection sites, which over time can cause lipohypertrophy — firm lumps of fatty tissue that alter drug absorption and create visible cosmetic irregularities. Using a simple site rotation chart or alternating between left and right sides weekly can prevent this. Another frequent error is injecting too quickly and removing the needle before the full dose has been delivered. With pen injectors, patients must hold the injection button for at least 6 seconds after the counter reaches zero; withdrawing early can result in medication leaking from the injection site, meaning you receive less than the intended dose. Air bubbles in syringes (for vial users) are a common concern. Small air bubbles in a subcutaneous injection are generally not medically dangerous — they will be absorbed by the body — but they do displace medication volume, meaning your dose may be slightly less than intended. Always tap the syringe and push out air before injecting. Injecting into muscle rather than subcutaneous fat is another mistake, particularly in lean individuals. Intramuscular injection can cause more pain and may alter absorption kinetics. If you have minimal subcutaneous fat, use a 45-degree angle and shorter needle length. Storing pens with the needle attached, skipping the pen safety test, reusing needles (which become dulled after a single use, increasing pain and infection risk), and failing to check the solution for clarity before injection are all avoidable errors. Finally, inconsistent injection timing — varying the day of the week — can contribute to fluctuating blood levels and increased side effects. Set a weekly reminder to maintain consistent dosing.

• Not rotating sites: causes lipohypertrophy and inconsistent absorption
• Withdrawing needle too quickly: results in dose leakage and underdosing
• Skipping pen safety test: may deliver air instead of medication
• Reusing needles: increases pain, risk of infection, and dose inaccuracy
• Injecting into muscle: causes more pain and may alter absorption
• Inconsistent timing: set a weekly alarm for the same day and approximate time

When to Seek Medical Attention

While semaglutide injections are generally well-tolerated, certain symptoms warrant prompt medical evaluation. Severe, persistent abdominal pain that radiates to the back — especially if accompanied by nausea and vomiting — may indicate acute pancreatitis, a rare but serious adverse event reported in post-market surveillance of GLP-1 receptor agonists. Seek emergency care immediately if you experience these symptoms. Signs of a serious allergic reaction (anaphylaxis) include difficulty breathing, swelling of the face, lips, tongue, or throat, rapid heartbeat, severe rash or hives, and dizziness or fainting. Although rare with semaglutide, anaphylaxis requires immediate emergency treatment. Injection site reactions that go beyond mild, transient redness — such as increasing pain, swelling, warmth, or redness spreading outward over 24-48 hours — may indicate a localized infection and should be evaluated by a healthcare provider. Persistent or severe nausea, vomiting, or diarrhea that prevents adequate fluid intake can lead to dehydration and acute kidney injury, which has been reported in patients taking GLP-1 agonists who became severely dehydrated. Contact your provider if you cannot keep fluids down for more than 24 hours. Changes in vision, particularly in patients with diabetic retinopathy, should be reported promptly, as rapid improvements in blood glucose control can temporarily worsen retinopathy. A lump or swelling in the neck, hoarseness, difficulty swallowing, or shortness of breath could be signs of thyroid changes and should be evaluated immediately given the boxed warning about thyroid C-cell tumors observed in rodent studies. Finally, symptoms of gallbladder disease — right upper abdominal pain, fever, and jaundice — have been associated with rapid weight loss on GLP-1 agonists and require medical assessment. This article is for educational purposes only and does not replace professional medical advice. Always consult your healthcare provider for guidance specific to your situation.

• Severe abdominal pain radiating to back: possible pancreatitis — seek emergency care
• Difficulty breathing, facial swelling, severe rash: possible anaphylaxis — call 911
• Expanding redness, warmth, or pus at injection site: possible infection
• Inability to keep fluids down for 24+ hours: risk of dehydration and kidney injury
• Vision changes in diabetic patients: report to provider promptly
• Neck lump, hoarseness, difficulty swallowing: seek immediate evaluation

References

1. Once-weekly semaglutide in adults with overweight or obesity (STEP 1) (2021) — PubMed
2. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6) (2016) — PubMed
3. Practical guide to GLP-1 receptor agonist injection technique (2019) — PubMed
4. Lipohypertrophy in insulin-treated patients: prevalence and risk factors (2013) — PubMed
5. Semaglutide prescribing information — Wegovy (FDA label) (2021)